Literature DB >> 12684739

Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.

Wynne K Schiffer1, Douglas Marsteller, Stephen L Dewey.   

Abstract

RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase. This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.
OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).
METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout. Finally, we examined the low dose of 150 mg/kg (50 mg/kg per day) using a similar washout period.
RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.
CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684739     DOI: 10.1007/s00213-003-1446-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Visual field defect associated with vigabatrin: observational cohort study.

Authors:  L V Wilton; M D Stephens; R D Mann
Journal:  BMJ       Date:  1999-10-30

2.  Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?

Authors:  L Giordano; D Valseriati; A Vignoli; F Morescalchi; E Gandolfo
Journal:  Neurol Sci       Date:  2000-06       Impact factor: 3.307

3.  No reversion in vigabatrin-associated visual field defects.

Authors:  I Nousiainen; M Mäntyjärvi; R Kälviäinen
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

4.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

5.  Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors.

Authors:  P J Schechter; Y Tranier; M J Jung; P Böhlen
Journal:  Eur J Pharmacol       Date:  1977-10-15       Impact factor: 4.432

6.  Failure of baclofen to modulate discriminative-stimulus effects of cocaine or methamphetamine in rats.

Authors:  P Munzar; S W Kutkat; C R Miller; S R Goldberg
Journal:  Eur J Pharmacol       Date:  2000-11-17       Impact factor: 4.432

7.  The effect of vigabatrin on brain and platelet GABA-transaminase activities.

Authors:  J B Bolton; E Rimmer; J Williams; A Richens
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Drug dependence study on vigabatrin in rhesus monkeys and rats.

Authors:  K Takada; T Yanagita
Journal:  Arzneimittelforschung       Date:  1997-10

9.  The legacy of vigabatrin in a regional epilepsy clinic.

Authors:  A Nicolson; J P Leach; D W Chadwick; D F Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

10.  One to three day dose intervals during subchronic treatment of epileptic gerbils with gamma-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels.

Authors:  W Löscher; H H Frey
Journal:  Eur J Pharmacol       Date:  1987-11-17       Impact factor: 4.432

View more
  8 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 3.  [New developments in the pharmacotherapy of cocaine dependence].

Authors:  G Wiesbeck; K Dürsteler-MacFarland
Journal:  Nervenarzt       Date:  2006-09       Impact factor: 1.214

4.  Genetic analysis of the psychostimulant effects of nicotine in chromosome substitution strains and F2 crosses derived from A/J and C57BL/6J progenitors.

Authors:  Alan E Boyle; Kathryn J Gill
Journal:  Mamm Genome       Date:  2008-12-13       Impact factor: 2.957

5.  Interaction of cocaine with positive GABAA modulators on the repeated acquisition and performance of response sequences in rats.

Authors:  M S Quinton; L R Gerak; J M Moerschbaecher; P J Winsauer
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

6.  Effects of pregnanolone in rats discriminating cocaine.

Authors:  M S Quinton; L R Gerak; J M Moerschbaecher; P J Winsauer
Journal:  Pharmacol Biochem Behav       Date:  2006-10-18       Impact factor: 3.533

7.  Tiagabine does not attenuate alcohol-induced activation of the human reward system.

Authors:  Christoph Fehr; Nina Hohmann; Gerhard Gründer; Thomas F Dielentheis; Hans-Georg Buchholz; Natalie Chechko; Igor Yakushev; Christian Landvogt; Peter Bartenstein; Reinhard Urban; Mathias Schreckenberger
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

8.  Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.

Authors:  Xiao-Qing Peng; Xia Li; Jie Li; P Veeraraghavan Ramachandran; Pravin D Gagare; Debarshi Pratihar; Charles R Ashby; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drug Alcohol Depend       Date:  2007-12-11       Impact factor: 4.492

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.